Evolución de sunitinib en 1ª línea en CCRm: Esquemas alternativos - page 32

Estudio RESTORE:

Respuesta

RR 2/1 47%

RR 4/2 33%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,22,23,24,25,26,27,28,29,30,31 33,34,35,36,37,38,39,40,41,42,...43